Publications
131
Citations
853
Est. group size
~16
Recurring co-author estimate
Active years
19
Publishing since 2008
Ashwini Esnakula works in pathology, focusing on the diagnosis and biomarker profiling of gastrointestinal and gynecologic cancers, including pancreatic, colorectal, and endometrial cancers. Their work spans diagnostic challenges in surgical pathology, biomarker discovery (such as serum MUC5AC and DNA methylation signatures for predicting treatment response), and educational/reference material distinguishing look-alike pathology diagnoses. Much of the recent output combines clinical case-based pathology teaching with translational cancer biomarker research.
Publication output has grown substantially over the last decade, rising from just a few papers per year before 2022 to over 30 per year in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Ectopic Splenic Tissue: Diagnostic Challenges in Limited Samples and Intraoperative Consultations
International Journal of Surgical Pathology · 2026
- 1381 Hepatic Epstein-Barr Virus–Associated Smooth Muscle Tumors: Insights from a Multi-Institutional Cohort
Laboratory Investigation · 2026
- Abstract 2743: Deploying artificial intelligence driven digital pathology for real world clinical decision-making in pancreatic cancer.
Cancer Research · 2026
- Interrater Reliability of the Nancy Histologic Index in Assessing Histologic Remission in Treated Ulcerative Colitis Biopsies: A Multi-institutional Experience Among Gastrointestinal Pathologists in the United States
Journal of Clinical and Translational Pathology · 2025
- My two cents on two vs four mismatch repair protein staining in endometrial cancer
American Journal of Obstetrics and Gynecology · 2025
- Serum mucin 5AC (MUC5AC) as a predictor of outcomes and microscopic distant metastasis in pancreatic ductal adenocarcinoma (PDA).
Journal of Clinical Oncology · 2025
- Prognostic significance of serum MUC5AC in resected pancreatic ductal adenocarcinoma: initial insights
Frontiers in Oncology · 2025
- Serum MUC5AC as a dynamic biomarker for tumor response, prognosis, and risk stratification in resected pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology · 2025
- MUC5AC profiling as a biomarker for predicting post-recurrence outcomes and guiding precision therapy in pancreatic ductal adenocarcinoma (PDA).
Journal of Clinical Oncology · 2025
- DNA methylation signatures as predictive biomarkers for chemotherapy (CT) resistance and survival in pancreatic ductal adenocarcinoma (PDA).
Journal of Clinical Oncology · 2025
- Upregulation of <i>GREB1</i> in colorectal cancer ovarian metastases may be a potential therapeutic target
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection Reporting of Adenocarcinoma in Polyp
Elsevier eBooks · 2025
- Tubular Adenoma With Squamoid Morules Versus Composite Adenoma-Microcarcinoid
Elsevier eBooks · 2025
- Tubular Adenoma Versus Endometriosis and Mucosal Colonization by Cancer
Elsevier eBooks · 2025
- Serrated Polyps Versus Adenomas
Elsevier eBooks · 2025
- Journal of Clinical Oncology×12
- Elsevier eBooks×12
- Cancers×5
- Gynecologic Oncology×4
- Cancer Research×4
- Ankur Sheel
Medicine · The Ohio State University
- Susan Tsai
Medicine · The Ohio State University
- Amir Sara
Medicine · The Ohio State University
- Susan Tsai
Medicine · The Ohio State University
- Ashish Manne
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile